Certara, a biosimulation technology-enabled drug development company, has merged its consulting group, Pharsight Consulting Services (PCS), with Quantitative Solutions, a global pharmacometrics consulting company headquartered in Menlo Park, CA.

The resulting organization, called Certara Strategic Consulting, expands Certara’s position in the growing modeling and simulation/pharmacometric services field, adding modeling capabilities, therapeutic areas of expertise, and new value-added services and clinical outcomes databases. Financial terms were not disclosed.
 
“Certara now offers the broadest array of modeling, simulation and strategic pharmacometric services from pre-clinical drug development through post-market approval,” said Certara chief executive officer o Edmundo Muniz, M.D., Ph.D. “The breadth, depth and innovative strengths of our newly formed consultancy are unsurpassed in the industry and will be leveraged as we work alongside our clients to bring safer and more efficacious therapies to patients.”
 
“The merger of Quantitative Solutions with Certara’s consulting group is exactly the type of strategic move our organization was ready for,” said Jaap Mandema, Ph.D., former chief executive officer of Quantitative Solutions, and new head of Certara Strategic Consulting. “Our integrated scientific consulting platform has the critical mass to allow for a quantum leap in the impact of modeling and simulation in drug development and beyond.” Dr. Mandema now reports directly to Dr. Muniz.